Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib vs Dupilumab in Adults with Moderate to Severe Atopic Dermatitis
2018-002264-57Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Upadacitinib arm with Dupilumab (Dupixent) arm (2 arms). Primary endpoint: EASI 75 at Week 16. Started Feb 2019; status: completed.
02
Drugs
upadacitinibdupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-002264-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002264-57.